NASDAQ:EIKN Eikon Therapeutics Q1 2026 Earnings Report $8.13 -0.85 (-9.47%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$8.21 +0.08 (+0.98%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Eikon Therapeutics EPS ResultsActual EPS-$2.46Consensus EPS -$1.47Beat/MissMissed by -$0.99One Year Ago EPSN/AEikon Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEikon Therapeutics Announcement DetailsQuarterQ1 2026Date5/11/2026TimeAfter Market ClosesConference Call DateMonday, May 11, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eikon Therapeutics Earnings HeadlinesEikon Therapeutics Stock: Will Upcoming ESMO Data Rekindle Investor Interest?September 23 at 10:26 PM | rttnews.comAnalysts Set Eikon Therapeutics, Inc. (NASDAQ:EIKN) PT at $25.00September 23 at 3:59 AM | americanbankingnews.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 24 at 1:00 AM | Paradigm Press (Ad)Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comInhibrx, Eikon rise after insider buyingSeptember 9, 2026 | msn.comMajor Investor Makes Bold Move on Eikon Therapeutics SharesSeptember 8, 2026 | tipranks.comSee More Eikon Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eikon Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eikon Therapeutics and other key companies, straight to your email. Email Address About Eikon TherapeuticsEikon Therapeutics (NASDAQ:EIKN) is a biotechnology company focused on discovering and developing medicines by combining advanced live-cell imaging with drug discovery and development. The company’s platform is designed to track individual molecules and cellular processes in real time, providing researchers with detailed insight into how potential therapies work inside living cells. Eikon applies this technology primarily to the development of treatments for serious diseases, including cancer and other conditions involving complex biological pathways. Its pipeline consists of investigational drug candidates, and the company’s programs remain subject to clinical testing and regulatory review rather than being marketed as approved products. Founded in 2019, Eikon is based in Hayward, California. The company was established by scientists including Nobel Prize-winning physicist Eric Betzig and has been led by Roger Perlmutter, who previously served as president of Merck Research Laboratories. Eikon’s research and development activities are focused on advancing its imaging platform and translating discoveries into potential therapies.View Eikon Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
